共 254 条
- [41] Zaid A(2021)Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON Cardiovasc Diabetol 78 63-undefined
- [42] Roubtsova A(2021)Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus Cardiovasc Diabetol 377 1007-undefined
- [43] Essalmani R(2017)Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans Circulation 6 undefined-undefined
- [44] Marcinkiewicz J(2014)Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Lancet 38 undefined-undefined
- [45] Chamberland A(2021)Inclisiran: a novel agent for lowering apolipoprotein b-containing lipoproteins J Cardiovasc Pharmacol undefined undefined-undefined
- [46] Hamelin J(2022)PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations BMJ undefined undefined-undefined
- [47] Sanz-Cuesta BE(2018)Inclisiran: a new promising agent in the management of hypercholesterolemia Diseases undefined undefined-undefined
- [48] Saver JL(2020)Inclisiran as adjunct lipid-lowering therapy for patients with cardiovascular disease: a cost-effectiveness analysis Pharmacoeconomics undefined undefined-undefined
- [49] Bergeron N(undefined)undefined undefined undefined undefined-undefined
- [50] Phan BA(undefined)undefined undefined undefined undefined-undefined